Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Wikipedia

CanSino Biologics

39°04′26″N 117°32′35″E / 39.0739°N 117.5430°E / 39.0739; 117.5430

CanSino Biologics Inc.
CanSinoBIO
Native name
康希诺生物
Founded2009; 15 years ago (2009) in Tianjin, China
Founders
  • Yu Xuefeng
  • Zhu Tao
  • Qiu Dongxu
  • Helen Mao Huihua
Headquarters185 South Avenue, TEDA West District,
Tianjin
,
China
Website

CanSino Biologics (simplified Chinese: 康希诺生物; traditional Chinese: 康希諾生物; pinyin: Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese vaccine company.[1]

History

edit

CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.[1]

In July 2018, it filed an application to list on the Hong Kong Stock Exchange.[1] It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017.[2] In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR market where it raised 5.2 billion yuan (US$750 million).[3]

Vaccines

edit

The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19.[1][4] The company has previously collaborated with the National Research Council of Canada (NRC) on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.[5][6][7]

COVID-19 vaccine development

edit
Main article: Convidecia
 
A multi-dose vial of CanSino's Convidecia vaccine for COVID-19 (AD5-nCOV) filled and finished in Mexico.

AD5-nCOV, trade-named Convidecia, is a single-dose[8] viral vector COVID-19 vaccine developed by CanSino. Since late 2020, it has been in Phase III trials in Chile,[9] Mexico,[10] Pakistan,[11] Russia,[12] and Saudi Arabia[11] with 40,000 participants.

In February 2021, global data from Phase III trials and 101 COVID cases showed that the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease.[13] It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial.[14][8] Its single-dose regimen and normal refrigerator storage requirement make it a favorable vaccine option for many countries.[14] The vaccine is approved for emergency use listing by the WHO.[15]

In April 2021, CanSino Biologics began clinical trials for a version of its Covid-19 vaccine administered by inhalation rather than injection.[16] Rollout of inhaled boosters began in China in October 2022.[17]

Convidecia is approved for use by some countries in Asia,[18][19][20] Latin America,[21][22][23] and by Hungary.[24][25] Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China,[26] Malaysia,[20] Mexico,[27][verification needed] and Pakistan.[28]

Investors

edit

As of 2018, CanSino Biologics investors included Lilly Asia Ventures, Qiming Venture Partners and SDIC Fund Management.[1]

See also

edit

References

edit
  1. ^ a b c d e Ng, Eric (25 July 2018). "Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal". South China Morning Post. Retrieved 18 April 2020.
  2. ^ Low, Zoe (29 March 2019). "Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China's domestic market". South China Morning Post. Retrieved 18 April 2020.
  3. ^ Ren, Daniel (13 August 2020). "Covid-19 vaccine maker CanSino soars in Star Market debut". South China Morning Post. Retrieved 15 August 2020.
  4. ^ Pinghui, Zhuang (10 April 2020). "Volunteers needed for second phase of China coronavirus vaccine trial". South China Morning Post. Beijing. Retrieved 18 April 2020.
  5. ^ Canada, National Research Council. "The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19". www.newswire.ca. Retrieved 19 May 2020.
  6. ^ "National Research Council contribution plays key role in newly approved Ebola vaccine". National Research Council Canada. 20 March 2018. The vaccine developed by CanSino is designed to provide protection against the strain of Ebola virus that caused the 2014 outbreak.
  7. ^ "Canada's surprising history and questionable partnership with a Chinese company and its military-backed COVID-19 vaccine". nationalpost. Retrieved 21 May 2021.
  8. ^ a b "It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective". Fortune. Retrieved 11 February 2021.
  9. ^ "Gob.cl - Article: Science Minister: "We Work With Maximum Rigor So That Science And Technology Benefit People'S Health"". Government of Chile. Retrieved 21 November 2020.
  10. ^ "Chinese Covid vaccine trials to be expanded to five more states". Mexico News Daily. 10 November 2020. Retrieved 11 November 2020.
  11. ^ a b "Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 21 October 2020.
  12. ^ "Russia approves clinical trials for Chinese COVID-19 vaccine Ad5-Ncov: Ifax". Reuters. 7 December 2020. Archived from the original on 7 December 2020. Retrieved 7 December 2020.
  13. ^ "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. 8 February 2021. Retrieved 8 February 2021.
  14. ^ a b "China's CanSino Covid Vaccine Shows 65.7% Efficacy". Bloomberg.com. 8 February 2021. Retrieved 10 February 2021.
  15. ^ "COVID-19 Vaccines with WHO Emergency Use Listing". WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). WHO. 3 November 2021. Archived from the original on 21 December 2021. Retrieved 10 April 2023.
  16. ^ "CanSino Biologics to start clinical trials of inhaled Covid-19 vaccine". Pharmaceutical Technology. 20 April 2021. Retrieved 15 February 2022.
  17. ^ Gao, Jiaxuan (December 2022). "Vaccination with CanSinoBIO's inhaled COVID-19 vaccine has begun in China". Journal of Biosafety and Biosecurity. 4 (2): 163. doi:10.1016/j.jobb.2022.12.002. PMC 9791787. PMID 36589793.
  18. ^ Liu, Roxanne (25 February 2021). "China approves two more domestic COVID-19 vaccines for public use". Reuters. Retrieved 26 February 2021.
  19. ^ "Pakistan purchases over 30 million COVID doses from China: sources". ARY NEWS. 25 April 2021. Retrieved 26 April 2021.
  20. ^ a b "Malaysia to receive CanSino vaccine this month | The Malaysian Insight". www.themalaysianinsight.com. Retrieved 3 April 2021.
  21. ^ "'Our gratitude always': From China's CanSino, Mexico welcomes biggest vaccine shipment yet". Reuters. 11 February 2021. Retrieved 11 February 2021.
  22. ^ "Argentina issues emergency approval to China's single-dose Cansino COVID-19 vaccine". Reuters. 11 June 2021. Retrieved 11 June 2021.
  23. ^ "ISP Approves Emergency Use And Importation Of Cansino Vaccine To Fight COVID-19". Institute of Public Health of Chile. Archived from the original on 7 April 2021. Retrieved 8 April 2021.
  24. ^ Ashok, Rashmi (22 March 2021). "UPDATE 2-China's CanSino Biologics COVID-19 vaccine receives emergency use approval in Hungary". Reuters. Retrieved 22 March 2021.
  25. ^ "Membrii NITAG au venit cu recomandări privind utilizarea vaccinurilor împotriva COVID-19 în Republica Moldova". Ministerul Sănătății, Muncii și Protecţiei Sociale. 3 March 2021. Retrieved 21 May 2021.
  26. ^ "China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year". finance.yahoo.com. 27 February 2021. Archived from the original on 27 February 2021. Retrieved 28 February 2021.
  27. ^ Solomon, Daina Beth (28 February 2021). "China's CanSino says first vaccines packaged in Mexico will be ready in March". Reuters. Retrieved 12 March 2021.
  28. ^ "Pakistan develops homemade anti-Covid vaccine 'PakVac'". The Express Tribune. 24 May 2021. Retrieved 25 May 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=CanSino_Biologics&oldid=1245390726"